Pediatrix Medical Group Target of Unusually Large Options Trading (NYSE:MD)

Pediatrix Medical Group, Inc. (NYSE:MD) was the target of unusually large options trading activity on Wednesday. Investors bought 6,020 put options on the stock. This represents an increase of approximately 1,686% compared to the average daily volume of 337 put options.

Pediatrix Medical Group Stock Up 7.7%

MD stock opened at $25.96 on Thursday. Pediatrix Medical Group has a fifty-two week low of $11.84 and a fifty-two week high of $27.94. The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of 12.60 and a beta of 0.66. The business’s fifty day moving average price is $23.80 and its two-hundred day moving average price is $22.13. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.33 and a quick ratio of 1.33.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a net margin of 9.02% and a return on equity of 19.94%. The firm had revenue of $476.20 million during the quarter, compared to the consensus estimate of $465.83 million. During the same quarter in the previous year, the firm posted $0.33 EPS. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. On average, equities analysts anticipate that Pediatrix Medical Group will post 2.1 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on MD. Jefferies Financial Group reiterated a “buy” rating and set a $27.00 price objective on shares of Pediatrix Medical Group in a research note on Monday, April 20th. Weiss Ratings reissued a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Wednesday, June 24th. UBS Group boosted their target price on shares of Pediatrix Medical Group from $22.00 to $25.00 and gave the stock a “neutral” rating in a report on Tuesday, May 12th. Truist Financial upped their price target on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a “hold” rating in a research report on Tuesday. Finally, Mizuho set a $24.00 price target on shares of Pediatrix Medical Group in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $23.33.

Insider Buying and Selling

In other news, Director Shirley A. Weis sold 36,028 shares of the stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $23.75, for a total transaction of $855,665.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Pediatrix Medical Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP increased its position in shares of Pediatrix Medical Group by 8.1% in the first quarter. Dimensional Fund Advisors LP now owns 3,856,915 shares of the company’s stock worth $82,496,000 after purchasing an additional 287,696 shares during the period. Wasatch Advisors LP lifted its position in Pediatrix Medical Group by 21.9% during the second quarter. Wasatch Advisors LP now owns 2,498,884 shares of the company’s stock worth $63,297,000 after purchasing an additional 448,360 shares during the period. Geode Capital Management LLC lifted its position in Pediatrix Medical Group by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 2,181,712 shares of the company’s stock worth $46,674,000 after purchasing an additional 14,421 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Pediatrix Medical Group by 7.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,552,585 shares of the company’s stock worth $33,210,000 after buying an additional 105,345 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Pediatrix Medical Group by 12.9% during the first quarter. Renaissance Technologies LLC now owns 1,532,300 shares of the company’s stock worth $32,776,000 after buying an additional 174,600 shares in the last quarter. 97.71% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Pediatrix Medical Group

Here are the key news stories impacting Pediatrix Medical Group this week:

• Positive Sentiment: Pediatrix Medical Group provided a second-quarter update saying its payor mix remained stable and unchanged versus recent historical trends, which should ease investor concerns about reimbursement or utilization pressures in the business. Pediatrix Medical Group Provides Second Quarter Update
• Positive Sentiment: Truist Financial raised its price target on MD from $23 to $28, signaling improved confidence in the stock’s outlook despite keeping a hold rating. Truist Financial Issues Positive Forecast for Pediatrix Medical Group (NYSE:MD) Stock Price
• Positive Sentiment: Zacks published additional commentary labeling Pediatrix Medical Group a strong long-term growth and momentum name, which may support sentiment among growth-oriented investors. Why Pediatrix Medical Group (MD) is a Top Growth Stock for the Long-Term
• Neutral Sentiment: Zacks also highlighted MD as a top momentum stock for the long term, reinforcing ongoing investor interest but not providing a new fundamental catalyst. Why Pediatrix Medical Group (MD) is a Top Momentum Stock for the Long-Term
• Negative Sentiment: Unusual options trading showed a surge in put buying, with traders purchasing 6,020 puts versus a typical 337, suggesting some market participants are positioning for downside risk or increased volatility.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.